Vpliv pooperativne radioterapije pri multimodalnem zdravljenju lokalnmo napredovalega raka dojke

Izpis gradiva
A+ | A- | | SLO | ENG

Naslov:	Vpliv pooperativne radioterapije pri multimodalnem zdravljenju lokalnmo napredovalega raka dojke
Avtorji:	ID But-Hadžić, Jasna (Avtor) ID Bilban-Jakopin, Cvetka (Avtor)
Datoteke:	PDF - Predstavitvena datoteka, prenos (240,99 KB) MD5: 10BB7E024537557199A5E794B51B9051 PID: 20.500.12556/dirros/740201f0-987a-4138-b61f-d33b753a2ca2
Jezik:	Slovenski jezik
Tipologija:	1.01 - Izvirni znanstveni članek
Organizacija:	OI - Onkološki inštitut Ljubljana
Status publikacije:	Objavljeno
Verzija publikacije:	Objavljena publikacija
Leto izida:	2008
Št. strani:	str. 89-93
Številčenje:	Letn. 12, št. 2
PID:	20.500.12556/DiRROS-8779
UDK:	616-006
ISSN pri članku:	1408-1741
URN:	URN:NBN:SI:doc-FHL0FV8M
COBISS.SI-ID:	25344473
Avtorske pravice:	by Authors
Opomba:	BSDOCID143368;
Datum objave v DiRROS:	31.08.2018
Število ogledov:	3475
Število prenosov:	790
Metapodatki:
:	Kopiraj citat

Objavi na:

Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Licenca:	CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna

Povezava:	http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:	To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:	31.08.2018

Jezik:	Ni določen
Naslov:	The impact of radiotherapy in multimodal management of locally advanced breast cancer
Povzetek:	We retrospectively analyzed the data from 55 patients treated for noninflammatory locally advanced breast cancer (LABC) with neoadjuvant chemotherapy and surgery with or without radiotherapy. The mean follow-up was 55 months. The purpose was to evaluate and compare the impact of postoperative radiotherapy, whether it was indicated on the basis of clinical stage at presentation of the disease or on downstaged pathological disease after initial chemotherapy. The 3-year overall survival (OS) was 74%, disease-free survival (DFS) 73% and relapse-free survival (RFS) 87%. The OS and DFS benefit was seen in those receiving radiation, with a mean OS of 89 months vs. 68 months (p=0.029) and mean DFS of 72 months vs. 54 months (p=0.029). Total LRR was 11% (8% vs. 17% in no RT group, p=0,349) and mean RFS of 95 months vs. 86 months (p=0.164). Significantly lower OS and DFS of the patients who were not treated with radiotherapy suggest that the indication for radiation treatment should be based on clinical pre-chemotherapy stage rather than pathological post-chemotherapy stage for non-inflammatory LABC.

niGradiv

Nazaj